Trial Profile
A Double-blind, Randomized, Multicenter, Active- and Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of CG100649 in Osteoarthritis Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Feb 2023
Price :
$35
*
At a glance
- Drugs Polmacoxib (Primary) ; Celecoxib
- Indications Osteoarthritis
- Focus Registrational; Therapeutic Use
- Sponsors CrystalGenomics
- 12 Jan 2016 Interim results published in CrystalGenomics media release.
- 09 Feb 2015 Based on the results of this trial, the South Korean Ministry of Food and Drug Safety (MFDS) has approved an NDA for polmacoxib (Acelex), according to a CrystalGenomics media release.
- 09 Feb 2015 Results published in CrystalGenomics media release.